{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:05:00Z","timestamp":1791669900456,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jpeds.2016.11.078","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T00:45:16Z","timestamp":1483058716000},"page":"296-303.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment"],"prefix":"10.1016","volume":"182","author":[{"given":"Brenda L.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Rybalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C.","family":"Shellenbarger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan M.","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Sawnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Jefferies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2016.11.078_bib0010","first-page":"1119","article-title":"Prevalence of Duchenne\/Becker muscular dystrophy among males aged 5-24 years - four states, 2007","volume":"58","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0015","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0883073810371004","article-title":"Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management","volume":"25","author":"Moxley","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pediatrneurol.2007.11.001","article-title":"Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up","volume":"38","author":"Houde","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0025","first-page":"9","article-title":"Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy","volume":"31","author":"Angelini","year":"2012","journal-title":"Acta Myol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0030","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(74)90071-3","article-title":"Prednisone in Duchenne muscular dystrophy","volume":"2","author":"Drachman","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0960-8966(91)90019-O","article-title":"Prednisone in Duchenne dystrophy","volume":"1","author":"Dubowitz","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0040","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.nmd.2004.05.001","article-title":"Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols","volume":"14","author":"Biggar","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0045","first-page":"16","article-title":"The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy","volume":"31","author":"McAdam","year":"2012","journal-title":"Acta Myol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/088307380201700306","article-title":"Corticosteroids in Duchenne muscular dystrophy: a reappraisal","volume":"17","author":"Wong","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1212\/01.WNL.0000148485.00049.B7","article-title":"Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society","volume":"64","author":"Moxley","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0070","first-page":"574","article-title":"Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases","volume":"38","author":"Swinyard","year":"1957","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0075","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.nmd.2012.07.009","article-title":"Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure","volume":"22","author":"Rutter","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0080","series-title":"Functional motor changes in Duchenne Muscular Dystrophy (DMD) patients on long term glucocorticoid (GC) treatment","first-page":"800","author":"Wong","year":"2013"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","article-title":"Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study","volume":"77","author":"Mazzone","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0095","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001338","article-title":"Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy","volume":"4","author":"Tandon","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0100","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2012.12.008","article-title":"All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy","volume":"61","author":"Schram","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","article-title":"Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade","volume":"16","author":"Biggar","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1991.00530160047012","article-title":"Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group","volume":"48","author":"Griggs","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0115","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.nmd.2004.05.006","article-title":"Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands","volume":"14","author":"Bushby","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0125","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0130","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study","volume":"85","author":"Bello","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0135","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1017\/S0007114510005180","article-title":"Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit","volume":"105","author":"Martigne","year":"2011","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.nmd.2011.02.006","article-title":"Endocrine aspects of Duchenne muscular dystrophy","volume":"21","author":"Bianchi","year":"2011","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-277X.2009.00979.x","article-title":"A review of nutrition in Duchenne muscular dystrophy","volume":"22","author":"Davidson","year":"2009","journal-title":"J Hum Nutr Diet"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0150","doi-asserted-by":"crossref","first-page":"867273","DOI":"10.1155\/2015\/867273","article-title":"Evidence of Insulin Resistance and Other Metabolic Alterations in Boys with Duchenne or Becker Muscular Dystrophy","volume":"2015","author":"Rodriguez-Cruz","year":"2015","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0155","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.nmd.2012.06.211","article-title":"T.P.51 Metformin reduces weight and BMI in Duchenne muscular dystrophy patients on long term glucocorticoid therapy","volume":"22","author":"Weatherspoon","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1399-5448.2009.00512.x","article-title":"Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit","volume":"11","author":"Casteels","year":"2010","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0165","series-title":"Long term growth hormone therapy in Duchenne Muscular Dystrophy (DMD): A case report","first-page":"754","author":"Lee","year":"2013"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1469-8749.2002.tb00272.x","article-title":"Fracture prevalence in Duchenne muscular dystrophy","volume":"44","author":"McDonald","year":"2002","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0175","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.11.078_bib0180","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.nmd.2012.06.354","article-title":"Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy","volume":"22","author":"Mayo","year":"2012","journal-title":"Neuromuscul Disord"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347616313865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347616313865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T07:55:57Z","timestamp":1536134157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347616313865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":35,"alternative-id":["S0022347616313865"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2016.11.078","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2016.11.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}